Three-component-multistage malaria vaccine

US10213501B2 · kind B2 · utility

Assignee

• Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. · DE

Inventors

• Holger Spiegel · Aachen, DE
• Alexander Boes · Cologne, DE
• Gueven Edgue · Aachen, DE
• Veronique Beiss · Aachen, DE
• Markus Sack · Aachen, DE
• Andreas Reimann · Krefeld, DE
• Rainer Fischer · Monschau, DE

Key dates

• Filing date: Sep 2, 2015
• Grant date: Feb 26, 2019
• Expiry date: Sep 2, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.